Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
GoodRx is now publicly available to trade. The stock opened at $46, nearly 40% above it's IPO price of $33.
Launched in 2011, GoodRx allows customers to compare prescription drug prices. It's since become a household name, which may be one of the reasons that the stock has been getting so much buzz. If you're planning to invest, here's how you can buy in.
|Latest market close||$44.13|
|52-week range||$26.66 - $64.22|
|50-day moving average||$38.89|
|200-day moving average||$36.67|
|Wall St. target price||$43.07|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-6.07%|
|1 month (2021-08-26)||24.70%|
|3 months (2021-06-25)||18.28%|
|6 months (2021-03-26)||16.04%|
|1 year (2020-09-25)||-15.20%|
|2 years (2019-09-22)||N/A|
|3 years (2018-09-22)||N/A|
|5 years (2016-09-22)||N/A|
Valuing GoodRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GoodRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GoodRx's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $79.1 million.
The EBITDA is a measure of a GoodRx's overall financial performance and is widely used to measure a its profitability.
To put GoodRx's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$631.1 million|
|Gross profit TTM||$521.1 million|
|Return on assets TTM||-21.43%|
|Return on equity TTM||-118.05%|
|Market capitalisation||$17.5 billion|
TTM: trailing 12 months
There are currently 15.9 million GoodRx shares held short by investors – that's known as GoodRx's "short interest". This figure is 2.3% down from 16.3 million last month.
There are a few different ways that this level of interest in shorting GoodRx shares can be evaluated.
GoodRx's "short interest ratio" (SIR) is the quantity of GoodRx shares currently shorted divided by the average quantity of GoodRx shares traded daily (recently around 1.8 million). GoodRx's SIR currently stands at 8.99. In other words for every 100,000 GoodRx shares traded daily on the market, roughly 8990 shares are currently held short.
To gain some more context, you can compare GoodRx's short interest ratio against those of similar companies.
However GoodRx's short interest can also be evaluated against the total number of GoodRx shares, or, against the total number of tradable GoodRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GoodRx's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 GoodRx shares in existence, roughly 40 shares are currently held short) or 0.2564% of the tradable shares (for every 100,000 tradable GoodRx shares, roughly 256 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against GoodRx.
Find out more about how you can short GoodRx stock.
We're not expecting GoodRx to pay a dividend over the next 12 months.
You may also wish to consider:
GoodRx Holdings, Inc. , through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.